

diurnal variations to his hallucinations, which were more frequent at night, or when he closed his eyes, and the fear of these has induced nyctophobia. In order to avoid these, he attempted to curtail closing his eyes or blinking. He had been treated with 9 different psychotropic medications, which had no effect on his hallucinations. Phenytoin was begun, and once therapeutic levels were achieved, all of his hallucinations resolved, as did his nyctophobia, with return to normal blink frequency.

RESULTS: Physical examination: Bilateral palmar erythema. Facial expression with decreased blink frequency, approximately 1/per minute, but not otherwise hypomimetic. Neurological examination: Cranial Nerve (CN) Examination: CN III, IV and VI: bilateral ptosis. Motor Examination: Normal tone without cogwheel rigidity. No bradykinesia. Drift Testing: Right upward-outward drift, right cerebellar spooning, and Abductor Digiti Minimi sign. Gait: Normal without instability or retropulsion. Reflexes: 1+ throughout. Hoffman Reflex: positive bilaterally. Other: Magnetic Resonance Imaging of brain with/without infusion: Normal. Five-day Electroencephalogram: Temporal Lobe Status Epilepticus with bilateral foci.

DISCUSSION: In this individual, the sheer terror of phantasmagoria with his eyes closed, forced him to maintain them in the open position as long as possible, reducing his blink frequency to once a minute or less. The return to a normal rate of blink frequency with treatment using phenytoin, with resolution of his horrific hallucinations, further validates this as the origin for his infrequent blinking. In those with low nictation, without other manifestations of Parkinson's disease, query as to volitional inhibition of blink frequency and nyctophobia is warranted.

38

Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia

Cherian Verghese, MD¹; Jean-Pierre Lindenmayer, MD²; Stephen R. Marder, MD³; Joshua Burke, MS⁴; Roland Jimenez, BA⁵; Chuck Yonan, PharmD⁶; Khody Farahmand, PharmD⁷; and Scott Siegert, PharmD⁸

¹ Principal Investigator, Keystone Clinical Studies, LLC, Norristown, PA

² Clinical Professor, Department of Psychiatry, New York University School of Medicine, New York, NY

³ Professor, Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA

⁴ Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA

⁵ Director, Clinical Programs, Neurocrine Biosciences, Inc., San Diego, CA

⁶ Senior Director, HEOR, Neurocrine Biosciences, Inc., San Diego, CA

⁷ Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA

⁸ Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA

ABSTRACT: Objective: Valbenazine (VBZ) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved to treat tardive dyskinesia (TD) in adults. It has been evaluated in 2 long-term studies (KINECT 3, KINECT 4) in which participants received VBZ (40 or 80 mg) for up to 48 weeks. This long-term rollover study (NCT02736955) was conducted to evaluate global TD improvement and patient satisfaction with once-daily VBZ.

METHODS: Key eligibility criteria: age 18 to 85 years; completion of KINECT 3 or KINECT 4; maintenance medications (for schizophrenia, schizoaffective disorder, or mood disorder) at stable doses; Brief Psychiatric Rating Scale score <50; no significant risk of active suicidal ideation or behavior. Following washout of prior VBZ treatment (Weeks 48 to 52 of KINECT 3 and KINECT 4), participants were re-initiated at 40 mg (4 weeks) and escalated to 80 mg based on tolerability and clinical assessment of TD; dose was reduced to 40 mg if 80 mg was not tolerated (80/40 mg). If unable to tolerate the 40 mg dose, the participant was discontinued. Participants received open-label VBZ for up to 72 weeks or until commercial availability. Assessments included Clinical Global Impression of Severity-TD (CGIS-TD: range, 1 ["normal, not at all ill"] to 7 ["among the most extremely ill patient"]) and Patient Satisfaction Questionnaire (PSQ: range, 1 ["very satisfied"] to 5 ["very dissatisfied"]).

RESULTS: 160 participants with available data were included in analyses (40 mg = 35; 80 mg = 117; 80/40 mg = 8); 138 were receiving treatment when VBZ became commercially available. The percentages of participants who completed visits at Wks 12, 24, 36, and 48 were 96.3%, 78.1%, 56.9% and 35.0%, respectively. Few reached Wk 60 (n = 4) or Wk 72 (n = 0) due to commercial availability. The percentage of participants with CGIS-TD score ≤2 ("normal, not at all ill" or "borderline ill") increased from baseline (before restarting VBZ) (40mg, 5.7%; 80mg, 18.1%) to Wk 48 (40 mg , 41.7%; 80 mg , 74.4%). At baseline, almost all participants rated their prior VBZ experience with a PSQ score ≤2 ("very satisfied" or "somewhat satisfied") (40 mg , 100%, 80 mg , 99.1%). Similar results were seen at the Wk 48 visit, with most participants continuing to express satisfaction with VBZ (40 mg , 100%; 80 mg , 97.4%).

CONCLUSIONS: A clinician-based global assessment indicated ongoing, meaningful TD improvements in adults who received once-daily VBZ in the current study. In participants treated for >1 year, continued patient satisfaction rates with VBZ were high.

Funding Acknowledgements: Neurocrine Biosciences, Inc.

39

Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia

Stephen R. Marder, MD¹; Martha Sajatovic, MD²; Dan Michel, PharmD³; Joshua Burke, MS⁴; Khody Farahmand, PharmD⁵; and Scott Siegert, PharmD⁶

¹ Professor, Psychiatry and Biobehavioral Sciences, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA

² Director, Neurological and Behavioral Outcomes Center, University Hospitals Cleveland Medical Center and Professor, Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH

³ Senior Medical Liaison, Neurocrine Biosciences, Inc., San Diego, CA

⁴ Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA

⁵ Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA

⁶ Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA

ABSTRACT: Objective: To evaluate the long-term safety and tolerability of once-daily valbenazine in adults with tardive dyskinesia (TD).

METHODS: Data were pooled from KINECT 3 (NCT02274558: 6-week double-blind placebo-controlled period, followed by a 42-week double-blind extension and 4-week drug-free washout) and KINECT 4 (NCT02405091: 48-week open-label treatment period and 4-week drug-free washout). KINECT 3/4 study completers could enroll in a subsequent rollover study (NCT02736955: up to 72 weeks of open-label treatment or until valbenazine became commercial available); data from this study were described separately for this analysis. Valbenazine dose groups (40 and 80 mg) were pooled for analysis. Safety assessments included treatment-emergent adverse events (TEAEs) and the Columbia-Suicide Severity Rating Scale (C-SSRS). Psychiatric status was assessed in KINECT 3 and KINECT 4 using the following measures: Positive and Negative Syndrome Scale (PANSS) total score and Calgary Depression Scale for Schizophrenia (CDSS) in participants with schizophrenia/schizoaffective disorder; Montgomery-Åsberg Depression Rating Scale (MADRS) and

Young Mania Rating Scale (YMRS) in participants with a mood disorder.

RESULTS: Analyses included 304 KINECT 3/4 participants and 160 rollover participants. In KINECT 3/4, the summary of TEAEs was as follows: any TEAE (71.7%), serious TEAE (16.8%), and discontinuation due to TEAE (15.5%). TEAEs reported in ≥5% of all KINECT 3/4 participants were headache (8.9%), urinary tract infection (8.9%), somnolence (7.9%), fatigue (6.3%), dizziness (5.9%), and suicidal ideation (5.6%). The summary of TEAEs from the rollover study was as follows: any TEAE (53.1%), serious TEAE (10.0%), and discontinuation due to TEAE (5.6%). The most common TEAEs in the rollover study were back pain and urinary tract infection (4.4%, each); no TEAE was reported in ≥5% of participants. Minimal changes in psychiatric status were observed in KINECT 3/4, as indicated by mean score changes from baseline to Week 48 in participants with schizophrenia/schizoaffective disorder (PANSS total, -3.2; CDSS total, -0.5) or a mood disorder (MADRS total, 0.3; YMRS total, -1.0). Over one-third of study participants had a lifetime history of suicidal ideation or behavior (KINECT 3/4, 41%; rollover, 38%). Most participants had no C-SSRS suicidal ideation at study baseline; of these, >90% had no emergence of suicidal ideation at any time during the study (KINECT 3/4, 93% [276/296]; rollover, 98% [153/156]).

CONCLUSIONS: Valbenazine was well tolerated and no unexpected safety signals were found in adults who received >1 year of once-daily treatment. Psychiatric stability was maintained, and few participants experienced any emergence of suicidal ideation during the studies despite 35–40% having a lifetime history of suicidality. These results indicate that once-daily valbenazine may be an appropriate treatment for the long-term management of TD.

Funding Acknowledgements: Neurocrine Biosciences, Inc.

40

Pseudo Cranial Nerve I Dysfunction: Subjective Hyposmia and Subjective Hypogeusia but Normosmia and Normogeusia - 3 cases

Kristal Benskin¹; and Alan R. Hirsch, M.D., F.A.C.P.²

¹ Medical Student, American University of Barbados School of Medicine, Bridgetown, Barbados, West Indies

² Smell and Taste Treatment and Research Foundation Ltd., Chicago, Illinois

ABSTRACT: INTRODUCTION: Hyposmia refers to reduced ability to smell and hypogeusia is a partial loss